Non-small cell lung cancer

News

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

Giving AstraZeneca's EGFR tyrosine kinase inhibitor (TKI) inhibitor Tagrisso in combination with chemotherapy to patients with EGFR-mutated non-small cell lung cancer (NSC

News

WCLC: Amgen eyes first-line use for KRAS drug Lumakras

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is und

News

WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s

AstraZeneca/Daiichi Sankyo and Gilead Sciences have reported preliminary results of studies that suggest their TROP2-targeted antibody-drug conjugates (ADCs) could have a

News

WCLC: Daiichi Sankyo HER3 ADC readout sets up filings

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the d

News

Roche seeks early-stage lung cancer use for Alecensa

Roche plans to file its Alecensa drug for use in early-stage ALK-positive non-small cell lung cancer (NSCLC), potentially making it the first targeted therapy for these pa

News

'Inadvertent' leak teases survival benefit for Roche's TIGIT

In an unusual development, Roche has put out a statement this morning acknowledging an "inadvertent disclosure" of data from its SKYSCRAPER-01 study of anti-TIGIT drug tir

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

WCLC: Amgen eyes first-line use for KRAS drug Lumakras

WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s

WCLC: Daiichi Sankyo HER3 ADC readout sets up filings

Roche seeks early-stage lung cancer use for Alecensa

'Inadvertent' leak teases survival benefit for Roche's TIGIT

UK, pharma industry pilot rapid access routes for medicines

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks